ArticleFrontiers in pharmacology2025
Burden of drug use disorders from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug use disorders (DUDs) represent a major public health challenge globally, including China. This study investigated the impact of DUDs in China over the past 3 decades and examined the long-term trends in their epidemiological characteristics. Methods: Data were obtained from the 2021 Global Burden of Disease (GBD) study. The burden of DUDs was assessed through Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), and Years Lived with Disability (YLDs). Joinpoint analysis was used to compute the Average Annual Percentage Change (AAPC), and Age-Period-Cohort analyses were conducted to illustrate trends in the burden of DUDs. A Bayesian Age-Period-Cohort model was fitted to forecast the anticipated burden. Results: From 1990 to 2021, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), and Age-Standardized Mortality Rate (ASMR) for DUDs in China demonstrated a consistent decline, with AAPC values of -0.76% (95% confidence interval [CI]: 0.83% to -0.69%), -1.05% (95% CI: 1.25% to -0.84%), and -4.41% (95% CI: 4.75% to -4.08%), respectively. Analysis of temporal trends indicated that the ASIR and ASPR for DUDs peaked between 1990 and 2000, followed by a variable decline, with a minor uptick noted from 2015 to 2021. The age-standardized DALY rates reached their zenith during 1990-2000. Additionally, analysis by age group indicated that from 1990 to 2021, the ASIR and ASPR for DUDs were highest among individuals aged 20-24 years, followed by a fluctuating decline. Gender-based analysis indicated that throughout this period, disease burden indicators for males consistently surpassed those for females. Projections from the Bayesian Age-Period-Cohort model suggest the ASIR will increase by 3.91% annually from 2022 to 2050, with growth rates of 4.54% for males and 3.25% for females. Conclusion: Between 1990 and 2021, China experienced a decline in the overall burden of DUDs. However, high incidence and prevalence rates persist, signifying an ongoing significant impact. By 2050, both incidence and prevalence rates of drug abuse are expected to increase significantly, necessitating a focus on the male population and the development of targeted prevention and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.